Xeris Biopharma Holdings (XERS) Inventory Average (2021 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Inventory Average came in at $71.5 million in Q1 2026, up 41.68% YoY from $50.4 million in Q1 2025, and up 4.97% on a QoQ basis from $68.1 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Inventory Average (2021 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 6 years of Inventory Average data on file, last reported at $71.5 million in Q1 2026.
- Quarterly Inventory Average rose 41.68% year-over-year to $71.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.5 million (up 41.68% YoY) and the FY2025 annual result came in at $58.4 million, up 34.29% from the prior year.
- Inventory Average advanced to $71.5 million in Q1 2026, from $68.1 million in the prior quarter.
- In the past five years, Inventory Average ranged from a high of $71.5 million in Q1 2026 to a low of $17.4 million in Q2 2022.
- A 5-year average of $41.3 million and a median of $39.9 million in 2024 frame the typical range for Inventory Average.
- Annual changes were most pronounced in 2023 — Inventory Average jumped 96.49% — and 2024, when it grew 17.96%.
- Tracing XERS's Inventory Average over 5 years: stood at $22.4 million in 2022, then jumped by 71.62% to $38.5 million in 2023, then climbed by 21.19% to $46.6 million in 2024, then surged by 45.92% to $68.1 million in 2025, then increased by 4.97% to $71.5 million in 2026.
- The last three Inventory Average figures came in at $71.5 million (Q1 2026), $68.1 million (Q4 2025), and $67.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 1.41 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 3.20 Bn |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 2.56 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 8.99 Bn |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 186.05 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 3.93 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 84.35 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 1.74 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 824.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn | 77.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.58 Mn |
| Mar 31, 2026 | 71.45 Mn |
| Dec 31, 2025 | 68.07 Mn |
| Sep 30, 2025 | 67.37 Mn |
| Jun 30, 2025 | 59.99 Mn |
| Mar 31, 2025 | 50.43 Mn |
| Dec 31, 2024 | 46.65 Mn |
| Sep 30, 2024 | 44.05 Mn |
| Jun 30, 2024 | 41.93 Mn |
| Mar 31, 2024 | 39.86 Mn |
| Dec 31, 2023 | 38.49 Mn |
| Sep 30, 2023 | 37.34 Mn |
| Jun 30, 2023 | 32.79 Mn |
| Mar 31, 2023 | 26.89 Mn |
| Dec 31, 2022 | 22.43 Mn |
| Sep 30, 2022 | 19.00 Mn |
| Jun 30, 2022 | 17.38 Mn |
| Mar 31, 2022 | 17.50 Mn |
| Dec 31, 2021 | 16.18 Mn |